COGNITION THERAPEUTICS INC (CGTX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-04

Key Insights

CFO John Brendan Doyle executed a tax withholding transaction on 05/01/2026, disposing of 8,567 shares at $1.28 per share to cover RSU vesting obligations, indicating ongoing equity compensation activity.
Following this transaction, Doyle maintains direct beneficial ownership of 618,942 shares, demonstrating substantial personal investment and confidence in the company despite the share disposition being tax-driven rather than voluntary selling.
The transaction represents a routine tax withholding event rather than discretionary insider selling, which has minimal predictive value for future stock performance or insider sentiment about company prospects.
At a price of $1.28 per share during the withholding, the stock appears to be trading at depressed levels, potentially reflecting biotech sector challenges or company-specific headwinds given CGTX operates in the therapeutics space.

Want the newest filings?

This analysis covers the filing from 2026-05-04. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-18

The reporting person, Anthony Caggiano, who is the Chief Medical Officer of Cognition Therapeutics Inc., disposed of 4,680 shares of common stock through a share withholding transaction to cover tax obligations.
The reporting person still holds a significant direct ownership stake of 864,906 shares in the company, indicating continued alignment with shareholder interests.
The transaction was executed at a price of $1.12 per share, which appears to be in line with the current market price.

Filed: 2026-02-18

The reporting person, John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc., has disposed of 1,560 shares of the company's common stock through a share withholding transaction to cover tax obligations.
This transaction reduces Doyle's direct beneficial ownership of Cognition Therapeutics' common stock to 617,509 shares.
Insider transactions, such as this share disposal, can provide insights into management's views on the company's valuation and future prospects.

Filed: 2026-02-18

Lisa Ricciardi, the CEO and President of Cognition Therapeutics, sold 5,850 shares of the company's common stock at $1.12 per share, suggesting potential insider selling activity.
Ricciardi still holds a significant stake in the company, with 1,706,676 shares beneficially owned directly and an additional 38,851 shares held indirectly through her spouse.
The transaction was made to cover tax withholding obligations in connection with the vesting of restricted stock units, indicating a common practice for executive compensation management.

Filed: 2026-02-05

Anthony Caggiano, the Chief Medical Officer of Cognition Therapeutics Inc., acquired 400,000 shares of the company's common stock at no cost through restricted stock units (RSUs).
Caggiano also disposed of 38,407 shares to cover tax withholding obligations, reducing his direct ownership to 869,586 shares.
The timing and amount of Caggiano's RSU acquisition and share dispositions suggest his confidence in the company's future prospects and alignment with shareholder interests.

Filed: 2026-02-05

John Brendan Doyle, the Chief Financial Officer of Cognition Therapeutics Inc., has acquired 200,000 shares of the company's common stock through restricted stock units (RSUs), increasing his direct ownership to 645,990 shares.
Doyle also disposed of 26,921 shares to cover tax withholding obligations, reducing his direct ownership to 619,069 shares.
The acquisition of shares through RSUs and the disposition of shares to cover taxes suggest Doyle's continued commitment to the company and alignment with shareholder interests.

Filed: 2026-02-05

Lisa Ricciardi, the CEO and President of Cognition Therapeutics Inc., acquired 800,000 shares of the company's common stock at no cost, indicating confidence in the company's future prospects.
Ricciardi also disposed of 26,036 and 51,704 shares on February 3 and 4, 2026, respectively, likely to cover tax withholding obligations, suggesting a partially cash-funded compensation structure.
The company's insider ownership increased, with Ricciardi's spouse holding an additional 38,851 shares, potentially aligning the leadership's interests with those of shareholders.

Other reports for COGNITION THERAPEUTICS INC

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.